Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:10 PM ET 10-Q
Financial Results Neuphoria Therapeutics Inc. NEUP

Neuphoria Therapeutics Q1 2026 Results: Net Loss of $1.43M, Loss Narrows

Neuphoria Therapeutics Inc., formerly Bionomics Limited, completed its re-domiciliation from Australia to Delaware in December 2024. As of November 13, 2026, the company reported 5,411,334 shares of common stock outstanding and is currently pursuing a proposed merger with Scancell Holdings plc.

Key figure
Net loss $1.43M
4:10 PM ET 10-Q
Financial Results Biotricity Inc. BTCY

Biotricity Q2 2026 Results: Net Loss of $808K, Loss Widens

Biotricity Inc. reported revenue of $8.61 million for the six months ended September 30, 2026, a 11% increase year-over-year. Despite achieving positive income from operations of $0.50 million, the company recorded a net loss attributable to common stockholders of $2.02 million due to significant interest expenses and derivative liability adjustments.

Key figure
Net loss $808K
4:10 PM ET 8-K
Shareholder Meeting Automatic Data Processing Inc ADP

Automatic Data Processing Shareholder Meeting

Automatic Data Processing, Inc. held its Annual Meeting of Stockholders on November 11, 2026. Shareholders elected 13 directors to the board, approved executive compensation on an advisory basis, and ratified the appointment of Deloitte & Touche LLP as the independent accounting firm for the fiscal year beginning July 1, 2026.

4:09 PM ET 8-K
Investor Presentation Metagenomi Therapeutics, Inc. MGX

Metagenomi Therapeutics Investor Presentation

Metagenomi Therapeutics, Inc. has furnished a corporate presentation dated November 2026 to provide an update on its precision gene editing pipeline and strategic priorities. The presentation highlights the company's lead candidate MGX-001, upcoming IND filings, and the design of the INTEGR8 clinical trial.

4:09 PM ET 8-K
Financial Results Insight Molecular Diagnostics Inc. IMDX

Insight Molecular Diagnostics Financial Results

Insight Molecular Diagnostics reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center to support its decentralized testing thesis.

Term
Q3 2026
4:09 PM ET 8-K
Shareholder Meeting Gold.com, Inc. GOLD

Gold.com Shareholder Meeting

Gold.com, Inc. held its 2026 Annual Meeting of Stockholders on November 12, 2026, where shareholders elected ten directors to serve until the 2027 Annual Meeting. Stockholders also approved, on an advisory basis, the fiscal year 2026 compensation of the company's named executive officers with approximately 91.3% of votes cast in favor.

4:09 PM ET 8-K
Leadership Change Unity Bancorp Inc UNTY

Unity Bancorp Leadership Change

James Donovan retired as First Senior Vice President and Chief Lending Officer of Unity Bank, receiving a $182,000 lump-sum severance payment. Minsu Kim, previously the Bank's Chief Credit Officer, was appointed as the new Chief Lending Officer effective November 12, 2026. The company has commenced a search for a new Chief Credit Officer to fill the vacancy left by Kim's promotion.

4:09 PM ET 8-K
Leadership Change Origin Bancorp, Inc. OBK

Origin Bancorp Leadership Change

Origin Bancorp, Inc. has appointed Derek McGee as Chief Operating Officer, effective November 13, 2026. McGee, who joined the company in 2022 as Chief Legal Counsel, will now oversee legal, enterprise risk, and regulatory coordination functions. The company stated that McGee will not receive any additional compensation or benefits as a result of this promotion.

4:09 PM ET 8-K
Investor Presentation Community Trust Bancorp Inc CTBI

Community Trust Bancorp Investor Presentation

Community Trust Bancorp, Inc. (CTBI) is presenting at the Piper Sandler Financial Services Conference in Aventura, Florida on November 17, 2026. The company filed a formal investor presentation deck (Exhibit 99.1) containing current and historical financial results along with future performance goals.

4:09 PM ET 8-K
Loan & Debt Pro Dex Inc PDEX

Pro Dex $8.51M Debt Financing with UMB Bank, N.A.

Pro-Dex, Inc. entered into an amendment to its credit agreement with UMB Bank to consolidate the outstanding principal balances of two term notes into a single $8.51 million Term Note D. The amendment extends the maturity date to November 1, 2031, sets a fixed interest rate of 6.67% per annum, and extends the maturity of its revolving note to December 31, 2028.

Value
$8.51M
Counterparty
UMB Bank, N.A.
Term
through Nov 2031
4:09 PM ET 8-K
M&A Deal Hancock Whitney Corp HWC

Hancock Whitney M&A Deal with Trustmark Corporation

Hancock Whitney Corporation has entered into a definitive agreement to acquire Trustmark Corporation in an all-stock merger. Trustmark shareholders will receive 0.7463 shares of Hancock Whitney common stock for each share of Trustmark they own. Following the merger, Trustmark Bank will be merged into Hancock Whitney Bank, and five Trustmark directors will join the Hancock Whitney board.

Counterparty
Trustmark Corporation
4:09 PM ET 8-K
Investor Presentation Independent Bank Corp INDB

Independent Bank Investor Presentation

Independent Bank Corp. filed an investor presentation deck to be used at the Piper Sandler Financial Services Conference on November 17, 2026. The presentation highlights the company's $25.0 billion in total assets, its recent acquisition of Enterprise, and record operating EPS of $1.90 for the third quarter of 2026.

4:09 PM ET 8-K
Financial Results Dare Bioscience, Inc. DARE

Dare Bioscience Financial Results

Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.

Term
Q3 2026
4:09 PM ET 8-K
Clinical Trial Data Mira Pharmaceuticals, Inc. MIRA

Mira Pharmaceuticals Clinical Trial Data

MIRA Pharmaceuticals announced new pharmacological findings for its investigational oral drug candidate MIRA-55, demonstrating high receptor selectivity for CB2 over opioid and COX receptors. The expanded screening showed a 500-fold separation from opioid receptor interactions, supporting its development as a differentiated non-opioid treatment for inflammatory pain. The company is currently advancing IND-enabling activities with a target submission date in the first half of 2027.

4:09 PM ET 8-K
Financial Results Soluna Holdings, Inc SLNH

Soluna Holdings Financial Results

Insight Molecular Diagnostics (iMDx) reported Q3 2026 revenue of $559,000 and provided an update on its FDA de novo submission for GraftAssureDx. The company initiated patient enrollment in its GALACTIC registry study at UCLA Medical Center and appointed a new sales leader to prepare for a potential commercial launch.

Term
Q3 2026
4:09 PM ET 8-K
Financial Results Entrepreneur Universe Bright Group EUBG

Entrepreneur Universe Bright Group Financial Results

Entrepreneur Universe Bright Group reported Q3 2026 revenue of $0.68 million, a decrease from $1.22 million in the prior year period, resulting in a net loss of $0.22 million. The company noted contracting demand in certain consulting lines but saw initial contributions from its newly established Credit Services segment in Hong Kong.

Term
Q3 2026

“Our third quarter results reflected contracting demand in certain consulting service lines, while digital marketing services and our newly established Credit Services segment contributed revenue during the period. We will continue to manage our operations prudently, strengthen our service capabilities and pursue opportunities to expand our revenue base in line with our long-term business objectives.”

Guolin Tao, CEO of EUBG
4:09 PM ET 8-K
Investor Presentation Independence Realty Trust, Inc. IRT

Independence Realty Trust Investor Presentation

Independence Realty Trust, Inc. (IRT) has filed a slide presentation to be used in various upcoming investor meetings beginning November 16, 2026. The presentation is furnished under Item 7.01 as a Regulation FD disclosure to provide strategic and operational updates to the investment community.

4:09 PM ET 8-K
Loan & Debt W.W. Grainger, Inc. GWW

W.W. Grainger $400M Debt Financing with J.P. Morgan Securities LLC

W.W. Grainger, Inc. priced an underwritten public offering of $400 million in 5.400% Senior Notes due 2031. The company entered into an underwriting agreement with J.P. Morgan, U.S. Bancorp, and Wells Fargo, with the offering expected to close on November 19, 2026.

Value
$400M
Counterparty
J.P. Morgan Securities LLC, U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC
Term
through 2031
4:09 PM ET 8-K
Financial Results Kyntra Bio, Inc. KYNB

Kyntra Bio Financial Results

Kyntra Bio reported Q3 2026 financial results, highlighting a cash position of $44.1 million and a runway extended into 2028. The company announced the discontinuation of its FG-3246 and FG-3180 programs due to insufficient efficacy, shifting focus toward a planned Phase 3 trial for roxadustat in early 2027. Additionally, the company restructured a royalty financing agreement, reducing its maximum payment obligation by $60 million.

Term
Q3 2026

“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial. We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial.”

Thane Wettig, Chief Executive Officer of Kyntra Bio
4:09 PM ET 8-K
Reverse Stock Split Treasure Global Inc TGL

Treasure Global Reverse Stock Split

Treasure Global Inc. implemented a 1-for-24 reverse stock split of its common stock effective November 16, 2026. The action is primarily intended to increase the per-share trading price to regain compliance with the Nasdaq minimum bid price requirement of $1.00 per share. The split reduced the company's outstanding shares from approximately 22 million to approximately 0.9 million.

4:09 PM ET 8-K
M&A Deal Aytu Biopharma, Inc AYTU

Aytu Biopharma M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.

Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals for $2.70 per share in an all-cash tender offer. The deal represents a 51.7% premium to Aytu's closing price on November 13, 2026, and is expected to close by the end of 2026. Upon completion, Aytu will become a wholly owned subsidiary of Rosemont, supporting Rosemont's U.S. growth strategy in the CNS and pediatric specialty pharmaceutical markets.

Counterparty
Rosemont Pharmaceuticals Holdings, Inc.
4:09 PM ET 8-K
Investor Presentation Public Storage PSA

Public Storage Investor Presentation

Public Storage announced that it has posted an investor presentation to its website on November 16, 2026. The company intends to use this presentation at an upcoming investor conference to provide strategic and operational updates to the market.

4:09 PM ET 8-K
Business Update Cardlytics, Inc. CDLX

Cardlytics Business Update

Cardlytics announced a workforce reduction of approximately 30 employees, or 15% of its staff, as part of a broader cost-reduction initiative. The company expects to incur $0.7 million in non-recurring severance charges while achieving approximately $12.2 million in annualized operating expense savings. The restructuring is expected to be substantially complete by the end of the fourth quarter of 2026.

4:09 PM ET 8-K
Stock Buyback Keros Therapeutics, Inc. KROS

Keros Therapeutics Announces $5M Stock Buyback

Keros Therapeutics announced that its Board of Directors approved a new $5 million share repurchase program for its common stock. The buyback authorization follows the company's receipt of a $20 million development milestone payment from Takeda Pharmaceuticals related to the clinical trial dosing of elritercept. Keros expects its current cash reserves, including this milestone, to fund operations into 2029.

Value
$5M
4:09 PM ET 10-Q
Financial Results 374Water Inc. SCWO

374Water Q3 2026 Results: Net Loss of $3.26M, Loss Narrows

374Water Inc. reported a significant revenue increase to $3.47 million for the nine months ended September 30, 2026, compared to $1.90 million in the prior year period. Despite improved gross margins, the company incurred a net loss of $10.53 million due to high operating expenses and a $1.02 million loss on debt extinguishment.

Key figure
Net loss $3.26M
4:09 PM ET 10-Q
Financial Results Sbig Holdings, Inc. SBIG

Sbig Holdings Q3 2026 Results: Net Income $3.21M, Up 1366.7% YoY

SBIG Holdings, Inc. reported a net income of $3.2 million for the quarter ended September 30, 2026, primarily driven by a $1.7 million gain from discontinued operations and a $1.6 million gain on troubled debt restructuring. The company transferred its operating subsidiary, SpringBig, Inc., in July 2026 and currently has no operating business or revenue as it seeks a strategic transaction.

Key figure
Net income $3.21M · +1366.7% YoY
4:09 PM ET 8-K
Financial Results Acrivon Therapeutics, Inc. ACRV

Acrivon Therapeutics Financial Results

Acrivon Therapeutics reported Q3 2026 financial results, ending the period with $77.8 million in cash and marketable securities, which is expected to fund operations into Q4 2027. The company highlighted its strategic expansion into immunology and inflammation (I&I) with the acquisition of ACR-525 and provided updates on its clinical pipeline, including upcoming Phase 2b interim data for ACR-368.

Term
Q3 2026

“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones.”

Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon
4:09 PM ET 10-Q
Financial Results FS Credit Real Estate Income Trust, Inc.

FS Credit Real Estate Income Trust Q3 2026 Results: Net Income $30.3M, Down 49.4% YoY

For the nine months ended September 30, 2026, FS Credit Real Estate Income Trust reported net income of $98.8 million, a decrease from $129.6 million in the prior year period. Total assets decreased to $11.4 billion from $11.8 billion at year-end 2025, primarily driven by a reduction in mortgage loans held in securitization trusts.

Key figure
Net income $30.3M · -49.4% YoY
4:09 PM ET 10-Q
Financial Results First Breach, Inc. FBDT

First Breach Q3 2026 Results: Net Loss of $25.3M, Loss Widens

First Breach, Inc. reported a significant increase in net loss to $53.8 million for the nine months ended September 30, 2026, driven by a surge in selling, general, and administrative expenses and stock-based compensation. Despite revenue growth to $0.93 million, the company maintains a negative gross margin and is currently operating as an early-stage, pre-net income entity.

Key figure
Net loss $25.3M
4:09 PM ET 10-Q
Financial Results International Land Alliance Inc. ILAL

International Land Alliance Q3 2026 Results: Net Loss of $1.57M, Loss Narrows

International Land Alliance Inc. reported net revenues of $2.20 million for the nine months ended September 30, 2026, but incurred a net loss of $8.27 million due to high general and administrative expenses and interest costs. The company's total assets remained stable at approximately $32.36 million, while stockholders' equity increased to $8.85 million following significant common stock issuances and debt conversions.

Key figure
Net loss $1.57M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.